Psychopharmacology

, Volume 129, Issue 3, pp 285–288

The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients

Authors

  • Paavo Riekkinen
    • Department of NeurologyUniversity Hospital of Kuopio
  • Hilkka Soininen
    • Department of NeurologyUniversity Hospital of Kuopio
  • Juhani Partanen
    • Department of Clinical NeurophysiologyUniversity Hospital of Kuopio
  • Ari Pääkkönen
    • Department of Clinical NeurophysiologyUniversity Hospital of Kuopio
  • Seppo Helisalmi
    • Unit of Clinical Genetics of the Department of Gynecology and ObstetricsUniversity Hospital of Kuopio
  • Paavo Riekkinen
    • A.I.Virtanen Institute, Department of NeuroscienceUniversity of Kuopio
Original Investigation

DOI: 10.1007/s002130050192

Cite this article as:
Riekkinen, P., Soininen, H., Partanen, J. et al. Psychopharmacology (1997) 129: 285. doi:10.1007/s002130050192

Abstract

In a previous study, we reported that Alzheimer disease (AD) patients with an apolipoprotein E (APOE) ɛ4 allele (+ APOE4) show more severe loss of nucleus basalis (NB) cholinergic cells than patients without ɛ4 alleles (− APOE4). The present study investigates the effects of a single oral administration of THA 25 or 50 mg on cortical spectral EEG activity in + (five APOE4/4, six APOE4/3) and − APOE4 (eight APOE3/3) AD patients. THA 25 mg had no significant effect on EEG activity in any AD patients. However, THA 50 mg increased alpha activity and alpha/theta ratio in − APOE4 patients. In contrast, THA 50 mg had no effect on EEG activity in + APOE4 patients. This result tentatively suggests that in AD patients APOE genotype may affect the response of cortical electrical arousal to cholinergic therapy that enhances the efficacy of presynaptic NB axons.

Key words

THAEEG slowingApolipoprotein EAlzheimer disease

Copyright information

© Springer-Verlag 1997